Market Overview - The Shanghai Composite Index closed at 3295.06 points, slightly below the five-day moving average, with a change of -0.07% [1] - The total trading volume of A-shares reached 1,137.01 billion yuan [1] Stocks Performance - A total of 514 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Jiuzhou Group (300040) with a deviation rate of 14.05% and a daily increase of 19.97% [1] - Zhejiang Huayuan (301535) with a deviation rate of 9.07% and a daily increase of 17.75% [1] - Nanguo Real Estate (002305) with a deviation rate of 7.92% and a daily increase of 10.32% [1] Detailed Stock Data - The following stocks have notable performance metrics: - Jiuzhou Group: Latest price 7.81 yuan, five-day moving average 6.85 yuan, turnover rate 43.12% [1] - Zhejiang Huayuan: Latest price 20.90 yuan, five-day moving average 19.16 yuan, turnover rate 58.83% [1] - Nanguo Real Estate: Latest price 1.39 yuan, five-day moving average 1.29 yuan, turnover rate 3.51% [1] - Other stocks with significant increases include: - Pulaia (603605) with a 10% increase and a deviation rate of 7.86% [1] - Fangda Group (000055) with a 9.95% increase and a deviation rate of 7.53% [1]

Group 1 - The Shanghai Composite Index closed at 3302.19 points, above the five-day moving average, with a slight increase of 0.15% [1] - The total trading volume of A-shares reached 733.14 billion yuan [1] - A total of 837 A-shares have prices that surpassed the five-day moving average, with notable stocks including Jiuzhou Group, Nanguo Real Estate, and Proya, showing significant deviation rates of 11.67%, 7.92%, and 7.86% respectively [1] Group 2 - The top stocks with the highest deviation rates from the five-day moving average include: - Jiuzhou Group (16.74% increase, 34.11% turnover rate, latest price 7.60 yuan, deviation rate 11.67%) [1] - Nanguo Real Estate (10.32% increase, 3.16% turnover rate, latest price 1.39 yuan, deviation rate 7.92%) [1] - Proya (10.00% increase, 2.50% turnover rate, latest price 84.71 yuan, deviation rate 7.86%) [1] - Other notable stocks with significant increases include: - Fangda Group (9.95% increase, 6.42% turnover rate, latest price 4.31 yuan, deviation rate 7.53%) [1] - Luolai Life (9.68% increase, 1.71% turnover rate, latest price 9.18 yuan, deviation rate 7.24%) [1]

智通财经4月25日电，早盘塞力医疗涨停，泓博医药、思创医惠涨超10%，创业慧康、朗玛信息、贝瑞 基因、卫宁健康、润达医疗等跟涨。消息面上，工信部等七部门关于印发《医药工业数智化转型实施方 案（2025—2030年）》提出，到2027年，医药工业数智化转型取得重要进展，以数智技术驱动的医药全 产业链竞争力和全生命周期质量管理水平显著提升。 AI医疗概念盘初活跃 塞力医疗涨停 ...

Core Viewpoint - Seer Medical has been penalized by the China Securities Regulatory Commission for failing to disclose related party transactions and fund occupation, resulting in a fine of 6 million yuan and a total penalty of 17.85 million yuan for responsible individuals [1][7]. Group 1: Regulatory Violations - Seer Medical was found to have serious undisclosed related party transactions and fund occupation from 2020 to mid-2022, providing funds to its controlling shareholder, Saihai Health Technology, under various pretenses [2][5]. - In 2020, the amount of occupied funds reached 121.3 million yuan, accounting for 7.48% of the audited net assets; in 2021, it was 132.25 million yuan (7.33%); and in the first half of 2022, it was 114.65 million yuan (6.58%) [5]. - The company failed to disclose significant contract signing matters in a timely manner, such as a 2022 equity transfer agreement that negatively impacted its net profit by approximately 12 million yuan, which was disclosed only in April 2023 [6]. Group 2: Financial Performance - Seer Medical has experienced continuous financial pressure, with net losses of 49.51 million yuan in 2021, 154 million yuan in 2022, and an expected loss of 210 to 250 million yuan in 2024 [9][12]. - The company has faced increasing competition in the IVD and medical service sectors, leading to difficulties in customer acquisition and revenue growth [12]. - High accounts receivable have severely impacted the company's financial status, with amounts exceeding 1.7 billion yuan from 2021 to 2023, resulting in increased credit impairment losses [12][13]. Group 3: Company Background and Development - Seer Medical was established in 2004 and has evolved into a leading player in the IVD industry, successfully listing on the Shanghai Stock Exchange in 2016 [8]. - The company has formed long-term partnerships with over 1,800 IVD manufacturers and collaborated with global pharmaceutical companies like Sanofi and COPAN [9]. - Despite its achievements, the company has struggled with operational challenges and strategic transitions, leading to a decline in profitability [12].

Group 1 - Seer Medical received an administrative penalty decision from the Hubei Regulatory Bureau of the CSRC due to related party transactions and fund occupation, revealing internal control deficiencies and governance issues within the company [1] - From 2020 to the first half of 2022, the company provided funds to its controlling shareholder, Saihai Health, amounting to 121.3 million yuan in 2020, 132.25 million yuan in 2021, and 114.65 million yuan in the first half of 2022, which accounted for 7.48%, 7.33%, and 6.58% of the latest audited net assets respectively [1] - A subsidiary transferred 51% of its equity in Zibo Seer to a third party without compensation, impacting the consolidated net profit attributable to the parent company by 12 million yuan, which represented 24.24% of the latest audited net profit [1] Group 2 - Kanglawei's application for marketing authorization of its three-valent HPV vaccine has been accepted by the National Medical Products Administration, marking the company's first submission for a vaccine [2] - The HPV vaccine market is highly competitive, with Merck's nine-valent HPV vaccine being the highest-priced approved vaccine, while domestic competitors are facing declining profitability [2] - The commercial returns from Kanglawei's three-valent HPV vaccine may be limited if approved [2] Group 3 - Kangfang Biotech announced significant positive results from its clinical study of the bispecific antibody drug Ivoris combined with chemotherapy for treating advanced squamous non-small cell lung cancer (sq-NSCLC) [3] - The study achieved the primary endpoint of progression-free survival (PFS) with statistically significant benefits, indicating a breakthrough in treatment options for sq-NSCLC patients [3] - Detailed data from the study will be presented at relevant international academic conferences [3] Group 4 - Lijuzhi Pharmaceutical's new class 1 drug NS-041 shows best-in-class potential as a next-generation KCNQ2/3 activator, demonstrating high selectivity and unique molecular design in preclinical and phase I studies [4] - NS-041 is set to enter phase II clinical trials to further explore its efficacy and safety in patients with focal epilepsy [4] - There are currently no new generation targeted KCNQ2/3 antiepileptic drugs on the market, highlighting the need for innovative treatment options [4] Group 5 - Baiyang Pharmaceutical plans to distribute a cash dividend of 7.62 yuan per 10 shares [5] Group 6 - In 2024, Baiyang Pharmaceutical achieved revenue of 8.094 billion yuan, with a net profit attributable to shareholders of 0.692 billion yuan, reflecting a year-on-year growth of 3.37% [6] - The company continues to focus on brand business, achieving revenue of 5.559 billion yuan, a year-on-year increase of 9.17% [6] - The core products of the company have shown double-digit year-on-year growth, indicating strong resilience in its development [6]

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-030 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于收到中国证券监督管理委员会湖北监管局 一、《行政处罚决定书》主要内容 "当事人：塞力斯医疗科技集团股份有限公司(以下简称塞力医疗)。住所： 湖北省武汉市东西湖区。 温伟，男，时任塞力医疗董事长、实际控制人，曾兼任公司总经理。住址： 湖北省武汉市江汉区。 王政，男，时任塞力医疗副总经理、董事兼总经理。住址：上海市黄浦区。 1 《行政处罚决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 塞力斯医疗科技集团股份有限公司（以下简称"公司"）于2024年3月25日 收到中国证券监督管理委员会（以下简称"中国证监会"）下发的《立案告知书》 （编号：证监立案字0052024002号）。因公司涉嫌信息披露违法违规，根据《中 华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会 决定对公司立案 ...

4月21日，塞力医疗今日收盘9.87元，上涨2.39%，最新市净率1.93，总市值18.85亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入14.20亿元，同比-7.15%；净利润-56025062.27 元，同比-1368.70%，销售毛利率19.89%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)2塞力医疗-8.94-11.891.9318.85亿行业平均 23.6322.711.80104.91亿行业中值18.9916.091.3056.98亿1漱玉平民-103.9232.812.1043.66亿3海王生 物-3.46-3.551.9859.99亿4柳药集团7.847.840.9067.01亿5鹭燕医药8.548.870.9530.65亿6国药股份 11.1111.111.30222.13亿7英特集团11.2911.041.2353.96亿8南京医药11.3611.360.9564.81亿9九州通 11.7311.040.97240.02亿10健之佳13.127.501.1231.06亿11百洋医药13.6715.654.65102.71亿 来源：金融界 股东方面，截至2024年 ...

塞力斯医疗科技集团股份有限公司关于"塞力转债" | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-029 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 经中国证券监督管理委员会（证监许可【2020】1033号）核准，公司于2020 年8月21日公开发行了543.31万张可转换公司债券，每张面值100元，发行总额 54,331万元，期限6年。本次发行的可转换公司债券的票面利率为：第一年0.50%， 第二年0.80%，第三年1.00%，第四年1.50%，第五年2.50%，第六年3.00%。 （二）可转换公司债券上市情况 经上海证券交易所自律监管决定书【2020】306号文同意，公司发行总额为 证券代码：603716 证券简称：塞力医疗 债券代码：113601 债券简称：塞力转债 当前转股价格：12.00元/股 转股起止日期：2021年3月1日至2026年8月20日 预计满足转股价格修正条件的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

塞力斯医疗科技集团股份有限公司的主营业务为集约化销售、单纯销售以及自主体外诊断产品的研发、 生产和销售。公司的主要产品为集约化IVD、集约化SPD等。 最新一期业绩显示，2024年三季报，公司实现营业收入14.20亿元，同比-7.15%；净利润-56025062.27 元，同比-1368.70%，销售毛利率19.89%。 4月16日，塞力医疗今日收盘9.61元，下跌4.47%，最新市净率1.88，总市值18.36亿元。 截至2024年三季报，共有1家机构持仓塞力医疗，其中基金1家，合计持股数10.00万股，持股市值0.01亿 元。 来源：金融界 序号股票简称PE(TTM)PE(静)市净率总市值(元)2塞力医疗-8.71-11.581.8818.36亿行业平均 22.3822.461.81105.36亿行业中值19.4316.011.2956.48亿1漱玉平民-103.3432.632.0843.41亿3海王生 物-3.43-3.521.9659.46亿4柳药集团7.807.800.8966.69亿5鹭燕医药8.418.300.9830.19亿6国药股份 11.0511.051.29220.92亿7南京医药11 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 一、募集资金基本情况 开发行可转换公司债券，募集资金总额为 543,310,000.00 元，扣除承销保荐费 （一）2018年非公开 用及与本次可转换公司债券发行直接相关的其他发行费用（不含增值税）后的 经中国证券监督管理委员会核发的《关于核准武汉塞力斯医疗科技股份有限公司非公开发行股票的批 复》（证监许可[2017]2322号）核准，塞力斯医疗科技集团股份有限公司（以下简称"公司"）于2018年 6月5日非公开发行A股股票26,853,709股，每股面值1元，发行价格为每股人民币23.31元，募集资金总额 为625,959,956.79元，扣除各项发行费用后实际募集资金净额人民币607,608,016.80元。上述资金已于 2018年6月5日全部到位，并经中审众环会计师事务所（特殊普通合伙）于2018年6月5日出具的众环验字 （2018）010040号验资报告审验。 募集资金净额为人民币 533,298,679.25 元。上述资金已于 2020 年 8 月 27 日全部到 ...